The effect of disease modifying therapies on CD62L expression in multiple sclerosis.

Margarete Maria VoortmanPaul GreinerDaniel MoserMartin Helmut StradnerWinfried GraningerAdrian MoserBernd HaditschChristian EnzingerSiegrid FuchsFranz FazekasJohannes FesslerMicheal Khalil

Published in: Multiple sclerosis journal - experimental, translational and clinical (2018)

CD62L+CD3+CD4+ expression is altered in patients treated with different disease-modifying therapies when measured in freshly collected samples. The clinical meaning of CD62L changes under disease-modifying therapies warrants further investigation.

Keyphrases

multiple sclerosis
poor prognosis
nk cells
binding protein
long non coding rna
white matter